Exact Sciences 650 Forward DR.

Exact Sciences starts scouting for a third lab site, CEO Kevin Conroy says

Exact Sciences Corp. hasn’t finished building its second big laboratory building to process Cologuard tests for colorectal cancer but the Madison cancer diagnostics company already is planning for lab No. 3.

And, in an unrelated move, Exact’s stock price topped $100 per share this week for the first time.

Exact has “begun evaluating potential sites to open a new lab,” CEO and chairman Kevin Conroy told a conference call with financial analysts this week.